Group (n = 6) | Compound and route of administration | Dose rate (mg/Kg) | Days of fecal sampling | |||||
−8 | 0* | 7 | 14 | 21 | 28 | |||
1 | Fosfatriclaben (IM) | 6 | 347 | 346 | 0 | 0 | 0 | 0 |
100 | 93 | 0 | 0 | 0 | 0 | |||
72 | 290 | 0 | 0 | 0 | 0 | |||
23 | 32 | 0 | 0 | 0 | 0 | |||
13 | 21 | 0 | 0 | 0 | 0 | |||
14 | 17 | 0 | 0 | 0 | 0 | |||
| Average |
| 94.83 | 133.17 | 0 | 0 | 0 | 0 |
| Efficacy (%) |
|
|
| 100 | 100 | 100 | 100 |
2 | Triclabendazole (PO) | 12 | 300 | 306 | 0 | 0 | 0 | 0 |
137 | 130 | 2 | 0 | 0 | 0 | |||
67 | 69 | 1 | 0 | 0 | 0 | |||
23 | 125 | 0 | 0 | 0 | 0 | |||
13 | 13 | 0 | 0 | 0 | 0 | |||
13 | 19 | 0 | 0 | 0 | 0 | |||
| Average |
| 92.16 | 110.33 | 0.5 | 0 | 0 | 0 |
| Efficacy (%) |
|
|
| 99.7 | 100 | 100 | 100 |
3 | Closantel (SC) | 10 | 212 | 730 | 0 | 0 | 0 | 0 |
170 | 167 | 0 | 0 | 0 | 0 | |||
58 | 266 | 0 | 0 | 0 | 0 | |||
30 | 33 | 0 | 0 | 0 | 0 | |||
89 | 110 | 15 | 8 | 5 | 7 | |||
14 | 15 | 0 | 0 | 0 | 0 | |||
| Average |
| 95.5 | 220.17 | 2.5 | 1.33 | 0.83 | 1.33 |
| Efficacy (%) |
|
|
| 98.8 | 99.5 | 99.7 | 99.5 |
4 | Control group | untreated | 373 | 383 | 432 | 436 | 442 | 462 |
89 | 161 | 601 | 778 | 761 | 760 | |||
78 | 76 | 187 | 180 | 188 | 192 | |||
21 | 57 | 54 | 135 | 128 | 125 | |||
15 | 42 | 40 | 54 | 56 | 56 | |||
21 | 17 | 18 | 56 | 55 | 60 | |||
| Average |
| 99.5 | 122.66 | 222 | 273.16 | 271.66 | 275.83 |